Publications
Detailed Information
Pharmacogenomic Approaches to Asthma Treatment
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Sang-Heon | - |
dc.date.accessioned | 2012-05-25T06:57:41Z | - |
dc.date.available | 2012-05-25T06:57:41Z | - |
dc.date.issued | 2010-07 | - |
dc.identifier.citation | ALLERGY ASTHMA & IMMUNOLOGY RESEARCH; Vol.2 3; 177-182 | ko_KR |
dc.identifier.issn | 2092-7355 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76481 | - |
dc.description.abstract | Major classes of medication in asthma management include bronchodilating beta 2-agonists, anti-inflammatory inhaled corticosteroids, leukotriene modifiers and theophyllines. However, all asthmatics do not respond to the same extent to a given medication. Available data suggest that a substantial range of individual variability, as much as 70%, may be due to genetic characteristics of each patient. Pharmacogenomics offers the potential to optimize medications for individual asthmatics by using genetic information to improve efficacy or avoid adverse effects. The best-studied case of the potential contribution of pharmacogenomics to treatment response in asthma comes from studies on human beta 2 adrenergic receptors. In addition, genetic variation in beta 2-adrenergic receptor (Arg16Gly) may predict response to anticholinergics for the treatment of asthma. In case of inhaled corticosteroids, a recent investigation using a traditional SNP-based approach identified a gene for corticotropin releasing hormone receptor 1 as a potential marker of response. Another major pathway that has been investigated is the pathway underlying response to cysteinyl leukotriene receptor antagonist. It is likely that in the near future, pharmacogenomic approaches based on individual genetic information will be introduced into an asthma treatment guideline and this guideline will allow us to identify those who have the best chance to respond to a specific medication. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | KOREAN ACAD ASTHMA ALLERGY & CLINICAL IMMUNOLOGY | ko_KR |
dc.subject | Asthma | ko_KR |
dc.subject | pharmacogenomics | ko_KR |
dc.subject | treatment response | ko_KR |
dc.title | Pharmacogenomic Approaches to Asthma Treatment | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 조상헌 | - |
dc.identifier.doi | 10.4168/aair.2010.2.3.177 | - |
dc.citation.journaltitle | ALLERGY ASTHMA & IMMUNOLOGY RESEARCH | - |
dc.description.citedreference | Lee SI, 2010, ALLERGY ASTHMA IMMUN, V2, P61, DOI 10.4168/aair.2010.2.2.61 | - |
dc.description.citedreference | Park HW, 2009, ALLERGY, V64, P778, DOI 10.1111/j.1398-9995.2008.01876.x | - |
dc.description.citedreference | Kapoor AS, 2009, CAN RESPIR J, V16, P99 | - |
dc.description.citedreference | JEE HM, 2009, PEDIAT ALLERGY RESP, V19, P165 | - |
dc.description.citedreference | Kang MJ, 2008, PHARMACOGENET GENOM, V18, P551 | - |
dc.description.citedreference | Iwamoto H, 2008, EUR RESPIR J, V31, P1379, DOI 10.1183/09031936.00014108 | - |
dc.description.citedreference | Bhavsar P, 2008, J ALLERGY CLIN IMMUN, V121, P580, DOI 10.1016/j.jaci.2007.12.1156 | - |
dc.description.citedreference | Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707 | - |
dc.description.citedreference | Kim JH, 2008, CLIN EXP ALLERGY, V38, P51, DOI 10.1111/j.1365-2222.2007.02874.x | - |
dc.description.citedreference | Bleecker ER, 2007, LANCET, V370, P2118 | - |
dc.description.citedreference | Lee SY, 2007, CLIN EXP ALLERGY, V37, P1487, DOI 10.1111/j.1365-2222.2007.02795.x | - |
dc.description.citedreference | Kim SH, 2007, PHARMACOGENOMICS, V8, P1143, DOI 10.2217/14622416.8.9.1143 | - |
dc.description.citedreference | Klotsman M, 2007, PHARMACOGENET GENOM, V17, P189 | - |
dc.description.citedreference | Cho SH, 2006, J KOREAN MED SCI, V21, P181 | - |
dc.description.citedreference | Wechsler ME, 2006, AM J RESP CRIT CARE, V173, P519, DOI 10.1164/rccm.200509-15190C | - |
dc.description.citedreference | Ito K, 2006, J ALLERGY CLIN IMMUN, V117, P522, DOI 10.1016/j.jaci.2006.01.032 | - |
dc.description.citedreference | Lugogo NL, 2006, CLIN CHEST MED, V27, P1, DOI 10.1016/j.ccm.2005.10.006 | - |
dc.description.citedreference | Lima JJ, 2006, AM J RESP CRIT CARE, V173, P379, DOI 10.1164/rccm.200509-1412OC | - |
dc.description.citedreference | Johnson M, 2006, J ALLERGY CLIN IMMUN, V117, P18, DOI 10.1016/j.jaci.2005.11.012 | - |
dc.description.citedreference | JOHNSON M, 2006, J ALLERGY CLIN IMMUN, V117, P25 | - |
dc.description.citedreference | Maxwell TJ, 2005, INT J MOL MED, V16, P573 | - |
dc.description.citedreference | Cho SH, 2005, CLIN EXP ALLERGY, V35, P1162, DOI 10.1111/j.1365-2222.2005.02319.x | - |
dc.description.citedreference | Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC | - |
dc.description.citedreference | Tantisira KG, 2004, HUM MOL GENET, V13, P1353, DOI 10.1093/hmg/ddh149 | - |
dc.description.citedreference | Currie GP, 2003, BRIT J CLIN PHARMACO, V56, P422 | - |
dc.description.citedreference | Bray PJ, 2003, HUM MUTAT, V21, P557, DOI 10.1002/humu.10213 | - |
dc.description.citedreference | Asano K, 2002, PHARMACOGENETICS, V12, P565 | - |
dc.description.citedreference | Ito K, 2002, AM J RESP CRIT CARE, V166, P392, DOI 10.1164/rccm.2110060 | - |
dc.description.citedreference | Fischer DD, 2002, J BIOL CHEM, V277, P6656, DOI 10.1074/jbc.M108055200 | - |
dc.description.citedreference | Taylor DR, 2000, THORAX, V55, P762 | - |
dc.description.citedreference | Israel E, 2000, AM J RESP CRIT CARE, V162, P75 | - |
dc.description.citedreference | Drazen JM, 2000, BRIT MED BULL, V56, P1054 | - |
dc.description.citedreference | Drazen JM, 1999, NAT GENET, V22, P168 | - |
dc.description.citedreference | Lima JJ, 1999, CLIN PHARMACOL THER, V65, P519 | - |
dc.description.citedreference | GREEN SA, 1994, BIOCHEMISTRY-US, V33, P9414 | - |
dc.description.tc | 3 | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.